常见中药复方制剂抗肝纤维化机制研究进展  

Mechanism research of common Chinese patent medicine antifibrotic

作　　者：李川[1] 吕文良[1] 

机构地区：[1]中国中医科学院广安门医院感染疾病科,硕士研究生北京100053

出　　处：《环球中医药》2013年第1期70-73,共4页Global Traditional Chinese Medicine

摘　　要：中药复方制剂具有多层次、多途径、多靶点抗肝纤维化的整体治疗优势,目前对中药复方制剂抗肝纤维化机制的研究仍然集中在通过各种途径抑制HSC增殖和活化、减少ECM的合成、加快细胞凋亡、抗脂质过氧化等方面。如何获得中药复方制剂抗肝纤维化的最大效益,需要运用细胞分子生物学、基因技术等手段对其抗肝纤维化机制进行进一步研究。There is a advantage for Chinese patent medicine to treat hepatic fibrosis by measures of multi-level, multl-channel, multl-target. At present, antlflbrotlc mechanism research of Chinese patent medicine is still concentrated in the inhibiting HSC proliferation and activation, reducing the synthesis of ECM, accelerating cell apoptosis, resisting lipid peroxidation through a variety of channels and so on. How to get the maximum benefit of Chinese patent medicine antifibrotic requires the use of cellular and molecular biology, gene technology and other means to further study its antifibrotic mechanism.

关 键 词：中药复方制剂 肝纤维化 机制 

分 类 号：R256.4[医药卫生—中医内科学]